The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

##STR00001##

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds. ##STR00001##

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Described are GCF-8 inhibitors of the formula (I),

##STR00001##

and pharmaceutically acceptable salts thereof, wherein n, R.sup.1, R.sup.2, R.sup.5, R.sup.6, X and Z are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for inhibiting GDF-8 in a cell and methods for treating a patient suffering from a disease or disorder, wherein the patient would therapeutically benefit from an increase in mass or strength of muscle tissue.

The invention relates to antibacterial compounds of formula I ##STR00001##
wherein R.sup.1 is H or halogen; R.sup.2 is alkynyloxy or the group M; R.sup.3 is H or halogen; M is one of the groups ##STR00002##
wherein A is a bond, CH.sub.2CH.sub.2, CH═CH or C≡C and R.sup.1A, R.sup.2A, R.sup.3A, R.sup.1B and R.sup.1C are as defined in claim 1;
and salts thereof.

The present invention relates to mito-lonidamine compounds, compositions and methods of use in the treatment of cancer.

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.

##STR00001##

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.

##STR00001##

The present invention relates to mito-lonidamine compounds, compositions and methods of use in the treatment of cancer.

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds. ##STR00001##